Periurethral injection of bulking agents to cause coaptation of the urethral walls has long been used in the treatment of urinary incontinence. A new form of this treatment is the silicone Genitourinary Spheroidal Membrane (Genisphere), which is placed in the periurethral tissues with a special delivery tool. Among 39 women who received two or three Genispheres, 29 (77%) became dry or markedly improved with a significant increase in leak-point and proximal urethral closure pressures. Early sexual activity, a short urethra, atrophic tissue, bladder instability, incorrect positioning, and device rupture were the causes of failure. The device has several advantages over traditional bulking agents, including the absence of silicone particles that can migrate, and has proved to be a safe method of treating stress urinary incontinence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/end.1996.10.283 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial Comment on "Outpatient Periurethral Injections of Polyacrylamide Hydrogel (Bulkamid) Under Local Anesthesia in the Office: A Prospective Single-center Series".
Urology
January 2025
LSU Health Foundation Board of Directors, LSU Department of Urology, New Orleans, LA. Electronic address:
Outpatient Periurethral Injections of Polyacrylamide Hydrogel (Bulkamid) Under Local Anesthesia in the Office: A Prospective Single-center Series.
Urology
November 2024
Department of Urology, University of Rennes, Rennes, France.
Objective: To report our experience of outpatient periurethral injections of Bulkamid under local anesthesia in the office in female patients for stress urinary incontinence (SUI). Polyacrylamide hydrogel (Bulkamid) is a relatively recent bulking agent which may have a better safety profile than previous generations.
Methods: The data of all women who underwent outpatient periurethral Bulkamid injections under local anesthesia in the office at a single academic center were collected prospectively between November 2019 and August 2023.
Long-term Outcomes of Periurethral Sphincter Botulinum Toxin in Female Chronic Urinary Retention.
Int Neurourol J
September 2024
Department of Uro Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
Article Synopsis
- Nonneurogenic chronic urinary retention is rare in young women, with Fowler syndrome being a primary cause, and while treatments like sacral neuromodulation are ideal, they aren't commonly accessible.
- A retrospective study reviewed 33 women treated with botulinum toxin A (BoTX-A) injections to address urinary retention due to Fowler syndrome over an 11-year period, finding that 64% of recipients responded positively after the treatment.
- The study concluded that periurethral botulinum toxin injections are a safe and effective long-term solution for managing this condition, offering a viable option when other treatments are unavailable.
Macroplastique® for stress urinary incontinence lights up as a PET-avid urethral lesion: A case report.
Case Rep Womens Health
October 2024
Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA.
Macroplastique® is a periurethral bulking agent used for the treatment of female stress urinary incontinence. It is composed of polydimethylsiloxane macroparticles suspended in a polyvinylpyrolidone carrier to allow injection. The patient in this case report had increased 18F-FDG avidity on PET scan at the site of prior Macroplastique® injection.
View Article and Find Full Text PDFOne-year outcomes of polyacrylamide hydrogel (Bulkamid) injection in women with stress and mixed urinary incontinence.
World J Urol
September 2024
Department of Urology, CH Aix-Pertuis, Aix en Provence, France.
Purpose: This study aimed to evaluate the efficacy and safety following treatment with Bulkamid for stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (MUI).
Methods: We retrospectively analyzed data of women diagnosed with SUI or stress-predominant MUI who underwent Bulkamid periurethral injection between November 2020 and January 2023 and completed 12 months of follow-up. The primary outcome of the study was to assess patient satisfaction, which was measured on a four-point scale, ranging from cured to worse, and through validated questionaries such as the International Consultation on Incontinence Questionnaire-short Form (ICIQ-UI SF) and Contilife Quality of Life questionnaire.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!